- PredxBio and Sirona Dx form a strategic partnership to reshape drug discovery and development.
- The collaboration leverages the SpaceIQ™ platform, combining spatial analytics with multiplex assay expertise.
- The aim is to identify spatial signatures in high-plex assays for therapy prediction and treatment decisions.
- Sirona Dx will act as a contract research organization (CRO) partner, deploying explainable AI-based diagnostic algorithms.
- Joint solutions to integrate genomic, proteomic, transcriptomic, and clinical data for spatial analysis in tumor microenvironment.
- The goal is to enhance prediction accuracies, accelerate biomarker discovery, and enable personalized care.
Main AI News:
In a strategic move set to redefine the landscape of drug discovery and development, PredxBio, Inc., a frontrunner in spatially intelligent biology, and Sirona Dx, a trailblazer in single-cell multi-omics analytical services, have unveiled a transformative partnership. This landmark collaboration heralds a new era in the industry by harnessing the power of Explainable AI-Driven Spatial Biology through the revolutionary SpaceIQ™ platform, unlocking the latent potential inherent in genomic, proteomic, and transcriptomic data via advanced spatial analytics.
The amalgamation merges PredxBio’s revolutionary spatial analytics platform, SpaceIQ™, with Sirona Dx’s unmatched proficiency in multiplex assay development. Together, they are poised to unearth groundbreaking spatial signatures within high-plex assays, prognosticating responses to therapy and guiding treatment strategies. Acting as a Contract Research Organization (CRO) partner, Sirona Dx will facilitate the deployment of Explainable AI-driven diagnostic algorithms to bolster biopharma clinical trials. By leveraging multiplex assay development alongside genomic and transcriptomic capabilities, the partnership aims to decipher spatial signatures within high-plex assays, thereby refining predictions of immunotherapy responses and instilling greater confidence in treatment regimens.
B. Dusty Majumdar, PhD, CEO of PredxBio, emphasized, “This partnership marks a pivotal moment in the spatial biology arena, where precision amalgamation with multimodal data is indispensable for unveiling the concealed intricacies within the tumor microenvironment. In collaboration with Sirona Dx, we endeavor to augment prediction accuracies and propel personalized therapeutic avenues, leveraging insights into the spatial tumor biology of individual patients through our pioneering SpaceIQ platform.”
Through this strategic synergy, Sirona Dx and PredxBio are poised to deliver state-of-the-art spatial analytics and elucidate AI-powered decisions at scale across the drug development spectrum. Their offerings will seamlessly integrate multimodal data, streamline clinical workflows, expedite biomarker discovery, and enable personalized care. The duo is primed to introduce a suite of solutions amalgamating genomic, proteomic, transcriptomic, and clinical data to dissect spatial heterogeneity within the tumor microenvironment (TME). These innovative methodologies will unveil crucial spatial interactions and microdomains within the TME, shedding light on disease progression and proliferation.
“We are excited to collaborate with PredxBio to elevate our precision amalgamation-based solutions, empowering biopharma endeavors and enhancing patient outcomes,” remarked Andrew Brown, Ph.D., Chief Commercial Officer at Sirona Dx. “Our combined prowess in multiplexing, explainable AI, and impartial spatial analytics is poised to revolutionize spatial biology, offering unprecedented insights to refine future immunotherapy paradigms.”
Conclusion:
The strategic partnership between PredxBio and Sirona Dx signifies a significant advancement in the drug discovery market. By merging cutting-edge spatial analytics with multiplex assay expertise, the collaboration aims to revolutionize therapy prediction and treatment decisions. This innovative approach, leveraging advanced technologies like Explainable AI, is poised to accelerate biomarker discovery and pave the way for more personalized care in the pharmaceutical industry. As a result, this partnership is likely to have a transformative impact, driving advancements and reshaping standards in the drug discovery landscape.
